Published online Mar 22, 2023. doi: 10.5494/wjh.v11.i1.1
Peer-review started: November 26, 2022
First decision: January 31, 2023
Revised: February 11, 2023
Accepted: March 6, 2023
Article in press: March 6, 2023
Published online: March 22, 2023
Processing time: 114 Days and 0.6 Hours
Core Tip: Many studies have reported the role of adipokines in hypertension. Adipocytes and their variety of factors make contributions to the long-term regulation of blood pressure. The risk of hypertension and cardiovascular diseases increase due to obesity mainly central obesity. However, this review article only focuses on the major adipokines such as chemerin, visfatin, retinol-binding protein 4, plasminogen activator inhibitor-1, monocyte chemotactic protein-1, omentin-1, lipocalin-2, vaspin, progranulin, complement C1q tumor necrosis factor-related proteins, and nesfatin-1 role in hypertension which were not reported collectively. Further studies require to find the exact mechanism of action of these adipokines in hypertensive subjects and therapeutic approaches are required to control the increasing prevalence of hypertension with obesity, which ultimately reduces the incidence of obesity-associated hypertension and cardiovascular diseases.
